PSMA-1007

CAT:
804-HY-153550-01
Size:
5 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
PSMA-1007 - image 1

PSMA-1007

  • Description:

    PSMA-1007 is a prostate-specific membrane antigen (PSMA) ligand. 18F-labeled PSMA-1007 can be used as a PET tracer for prostate cancer imaging. PSMA-1007 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) [1].
  • UNSPSC:

    12352209
  • Target:

    PSMA; Radionuclide-Drug Conjugates (RDCs)
  • Type:

    Peptides
  • Related Pathways:

    Antibody-drug Conjugate/ADC Related; Immunology/Inflammation
  • Applications:

    COVID-19-immunoregulation
  • Field of Research:

    Cancer
  • Assay Protocol:

    https://www.medchemexpress.com/psma-1007.html
  • Purity:

    99.35
  • Solubility:

    DMSO : 125 mg/mL (ultrasonic)
  • Smiles:

    OC(CC[C@H](NC([C@@H](NC(C1=CC=C([N+](C)(C)C)N=C1)=O)CCC(O)=O)=O)C(NCC2=CC=C(C(N[C@@H](CC3=CC=C(C=CC=C4)C4=C3)C(NCCCC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O)=O)=O)C=C2)=O)=O.[O-]C(C(F)(F)F)=O
  • Molecular Formula:

    C54H64F3N9O18
  • Molecular Weight:

    1184.13
  • References & Citations:

    [1]Mamlins E, et al. PSMA-1007 Uptake in Ganglia of the Sympathetic Trunk and Its Intra-individual Reproducibility. Mol Imaging Biol. 2023 Jun;25 (3) :554-559. |[2]Kim SB, et al. Preclinical Evaluation of a Companion Diagnostic Radiopharmaceutical, [18F]PSMA-1007, in a Subcutaneous Prostate Cancer Xenograft Mouse Model. Mol Pharm. 2023 Feb 6;20 (2) :1050-1060.
  • Shipping Conditions:

    Blue Ice
  • Storage Conditions:

    -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
  • Scientific Category:

    Peptides
  • Clinical Information:

    Phase 3
  • CAS Number:

    [2226894-58-0]